XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Last 30 days: 89 accesses
Last 365 days: 763 accesses
All time: 3497 accesses

A del Giglio, A Eniu, D Ganea-Motan, E Topuzov and H Lubenau^*